Abstract Transforming growth factor-b (TGFb) is a secreted cytokine implicated as a factor in cancer cell migration and invasion. Previous studies have indicated that TGFb isoforms may exert differential effects on cancer cells during different stages of the disease, however very little is known about the expression patterns and activity of the three isoforms in prostate cancer. Non-traditional signaling pathways including the PI3-Kinase have been associated with TGFb-mediated effects on cancer cell invasion. In the present study, we have carried out expression analysis of TGFb isoforms and signaling components in cell line models representing different stages of prostate cancer and studied the differential effects of specific isoforms on migratory and invasive behavior and induction of the PI3-kinase pathway. TGFb1 and TGFb3 were expressed in all cell lines, with TGFb3 expression increasing in metastatic cell lines. Both TGFb1 and TGFb3 induced motility and invasive behavior in PC3 cells, however, TGFb3 was significantly more potent than TGFb1. TGFbRI and Smad3 inhibitors blocked TGFb1 and TGFb3 induced motility and invasion. TGFb3 caused a significant increase in pAKT ser473 in PC3 cells and PI3-kinase inhibitor LY294002 blocked TGFb3 induced migration, invasion and phosphorylation of AKT. Both TGFbRI and Smad3 inhibitors blocked TGFb3 induced pAKT ser473 . Based on these results, we conclude that TGFb3 is expressed in metastatic prostate cancer cell lines and is involved in induction of invasive behavior in these cells. Furthermore, these effects of TGFb3 are TGFbRI and Smad3 dependent and mediated via the PI3-kinase pathway.
Introduction
Transforming growth factor-b (TGFb) is a secreted cytokine involved in the regulation of many cellular processes and has been implicated as a factor in cancer formation and progression [1, 2] . TGFb exerts pleiotropic effects on numerous cellular functions that include differentiation, proliferation, motility and extracellular matrix (ECM) production in many normal cell types [3, 4] . In normal epithelial cells and early stage cancers, TGFb inhibits cell proliferation and acts as a tumor-suppressor [1, 5, 6] . However, in later stages of many cancers, the tumor cells become resistant to growth inhibitory effects of TGFb. In these cells, TGFb can act as a tumor promoter due to its role in stimulating angiogenesis, epithelial to mesenchymal transformation (EMT), or promoting the degradation of ECM; all of which aid in invasion and metastasis [2, 7, 8] .
The three TGFb isoforms, TGFb1, TGFb2 and TGFb3, share a 70-80 % sequence homology in most organisms and are expressed throughout most mammalian tissues [3, 4, 9] . Of the three isoforms, TGFb1 is the most commonly studied and tends to be ubiquitously expressed among cell lines and in diseased tissues such as cancer [10, 11] . In numerous in vitro studies, all three isoforms bind to the same receptors and exert similar biological effects on target cells [12] . However, TGFb isoforms can have non-redundant specific effects during development as indicated by gene knock-out studies [13] [14] [15] [16] . Binding affinity studies show that the three isoforms signal by binding to TGFbRI and TGFbRII [17] however, TGFb2 differs from TGFb1 and TGFb3 in that it binds to TGFbRII with an affinity that is 100-1,000 fold lower and requires TGFbRIII (b-glycan) to promote receptor assembly with TGFb2 [9, [18] [19] [20] [21] [22] . Additionally, crystal structure of TGFbRII-TGFb3 complex showed that interfacial residues of TGFb3 are identical to TGFb1 but are different than TGFb2 at three positions [23] . These studies suggest that although both TGFb1 and TGFb3 share a significant homology, receptor binding affinity and can exert similar biological effects on target cells, they may retain the ability to have nonredundant differential effects.
Earlier studies have indicated that individual TGFb isoforms may exert differential effects on cancer cells during different stages of the disease. In one such study, TGFb3 increased the invasiveness of endometrial carcinoma cells via a PI3-kinase-dependent pathway, and these effects were distinct from those of TGFb1 [24] . In prostate cancer, there is very little known about the expression levels of the three isoforms, specifically TGFb3, in prostate cancer cell lines and clinical tissue samples. Evidence indicates that TGFb3 expression increases 2 fold in prostate tumors and that the TGFb3 gene is over-expressed in an androgen-independent derivative of prostate cancer cell line compared to the androgen-dependent parental cell line [25] .
Recent studies have suggested the involvement of the phosphatidylinositol 3-kinase (PI3-kinase) pathway in TGFb-mediated effects on cancer cell invasion and metastasis. PI3-kinase has been shown to play an integral role in many cellular processes including cell proliferation, growth and survival in both normal and diseased tissues [26, 27] . Activating mutations of the PI3-kinase pathway and loss of PTEN are common in many types of cancers and are associated with tumor progression [28] . It has been shown that TGFb can activate PI3-kinase, as determined by increased phosphorylation of AKT, a downstream target of PI3-kinase [29] [30] [31] [32] [33] . Prior studies have also revealed that TGFb isoform-specific effects on the PI3-kinase pathway can be either dependent or independent of Smad signaling depending on the experimental conditions and cellular context [24, 32, 33] . The PI3-kinase pathway has also been implicated as a contributing pathway to TGFb induced EMT as well as fibroblast proliferation and morphological transformation [33] , all precursors to invasion and metastasis. Whether or not TGFb isoforms play a differential role in invasion and metastasis of prostate cancer, and act through non-Smad pathways such as PI3-kinase, is still unclear.
In the present study, we have carried out a detailed analysis of the expression of TGFb isoforms and signaling components in cell line models representing different stages of prostate cancers and have studied the differential effects of specific isoforms on migratory and invasive behavior of prostate cancer cells. Our results indicate that TGFb effects on migration and invasion of prostate cancer cells are primarily induced by TGFb3 and that these effects are dependent on both TGFbRI and Smad3 and mediated via PI3-kinase pathway.
Materials and methods

Chemicals and reagents
Recombinant human TGFb1 and TGFb3 were purchased from R&D systems (Minneapolis, MN). Inhibitors of TGFbRI (SB431542) and Smad3 (SIS3) were purchased from Tocris Bioscience (Ellisville, MO) and EMD Biosciences (Gibbstown, NJ), respectively. Specific inhibitor of PI3-kinase (LY294002) was purchased from SigmaAldrich (St. Louis, MO). The antibodies against pAKTser473, AKT (pan), pSmad2, pSmad3 and Smad2/3 were purchased from Cell Signaling Technology (Beverly, MA). Antibodies against TGFb1, 2 and 3 were purchased from Peprotech (Rocky Hill, NJ). Anti-b-Actin (clone AC-15) antibody was purchased from Sigma-Aldrich (St. Louis, MO). Anti-rabbit IgG HRP was purchased from Bio Source (Camarillo, CA) and Anti-mouse IgG HRP was obtained from Promega (Madison, WI). Matrigel and invasion inserts were purchased from BD Biosciences (Bedford, MA). The HEMA 3 stat dye was purchased from Fisher (Pittsburgh, PA).
Cell lines and cell culture
Prostate cell lines LNCaP (prostate carcinoma), DU145 (prostate carcinoma), PC3 (prostate adenocarcinoma), RWPE1 (epithelial cells from histologically normal adult human prostate), RWPE2 (immortalized epithelial cells were derived from RWPE-1 cells by transformation with Ki-ras using the Kirsten murine sarcoma virus (Ki-MuSV)) and PZ-HPV7 (immortalized epithelial cells from histologically normal adult human prostate) were acquired from American Type Cell Culture Collection (Rockville, MD). PC3M cells (metastatic derivative of PC3) were kindly provided by Dr. Girish Shah (University of Louisiana). All cells were cultured in recommended growth medium at 37°C with 5 % C0 2 and 100 % humidity. DU145, PC3, and PC3M cells were cultured in Eagle's minimum essential medium (MEM) with Earle's salts with 0.1 mM of the necessary amino acid supplements as described previously [34, 35] . LNCaP cells were maintained in RPMI 1640 containing 4 mM glutamine and 50 lg/ml gentamycin. Both MEM and RPMI media (Mediatech, Herndon, VA) were supplemented with 5 % fetal bovine serum (FBS; HyClone, South Logan, Utah). RWPE1, RWPE2 and PZ-HPV7 were cultured in keratinocyte serum free medium (KSFM) containing 50 lg/ml gentamycin (Invitrogen) and with 0.05 mg/ml bovine pituitary extract and 5 ng/ml EGF.
RNA isolation, cDNA synthesis and RT-PCR For RT-PCR analysis, cells were seeded (5 9 10 5 /well) into 6-well plates overnight. Total RNA was isolated from the cells using TRIzol (Invitrogen) followed by chloroform extraction and isopropanol precipitation and quantified by optical density reading at 260 nm. OD 260 /OD 280 ratios were used for quality assessment of RNA preparations. Total RNA (2 lg) were reverse transcribed as previously described [36] . RT-PCR reactions were performed on I-Cycler IQ (BioRad, Hercules, CA). RT-PCR reactions were performed according to procedures described previously [34] . Gene encoding ribosomal protein L-19 was used as internal control. All gene-specific primers were designed with the assistance of the computer program Beacon Designer 5.0 (PremierBiosoft International, Palo Alto, CA) which was set to exclude regions of cross-homology against the non-redundant set of human genes from GenBank, EMBL, and DDBJ database sequences) and to exclude regions of significant secondary RNA structure. When possible, primer sets were designed to span long introns to avoid amplification of genomic DNA contamination. Sequences of all primers used in RT-PCR experiments are shown in Table 1 . The PCR products were visualized on 1-2 % agarose gels stained with ethidium bromide or on 4 % SFR agarose gels (Amresco, Solon, OH). Analyses of PCR products were carried out in three independent experiments using different cell preparations.
TGFb treatments
To determine the effects of TGFb isoforms on phosphorylation of AKT, DU145, PC3, and LNCaP cells were cultured in 6 well plates (5 9 10 5 cells/well) in 5 % FBS/ Medium and allowed to attach overnight. Cells were serum starved for 2 h and incubated with or without TGFbRI inhibitor (SB431542: 5 lM), Smad3 inhibitor (SIS3: 3 lM) or PI3-kinase inhibitor (LY294002: 10 lM) for 30 min. Phosphatase inhibitor (SodiumVanadate; 200 lM) was added 10 min prior to the treatment. Cells were then treated with TGFb1 or TGFb3 (5 ng/ml) over various time points. Cells were washed twice with ice-cold phosphatebuffered saline and lysed in lysis buffer (Cell Signaling Technology, Beverly, MA) containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1 % Triton, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Sodium Vanadate, 1 lg/ml leupeptin and 1X protease inhibitor cocktail (Calbiochem, San Diego, CA). Protein concentrations were determined by the Lowry HS assay using the Bio-Rad DC Protein Assay kit according to the instructions provided by the manufacturer.
Western blot analyses
Cell lysates were mixed with Laemmli buffer (62.5 mM Tris, pH 6.8, 2 % SDS, 5 % b-mercaptoethanol and 10 % glycerol) and individual samples (25-50 lg proteins) were subjected to SDS-PAGE in 8-10 % gels and transferred to PVDF membranes (Millipore, Billerica, MA). The membranes were blocked for 1 h in TBST (50 mM Tris, pH 7.5, containing 0.15 M NaCl, 0.05 % Tween 20) containing 5 % fat free skim milk. The blots were then incubated with appropriate dilutions of specific primary antibodies overnight at 4°C in TBST containing 5 % bovine serum albumin (BSA). After washing, blots were incubated with anti-rabbit or anti-mouse immunoglobulins coupled to horseradish peroxidase (dilution 1:10,000) in blocking buffer (TBST with 5 % milk) for 1 h and washed in TBST for 1 h. The blots were developed in SuperSignal West Pico chemiluminescent substrate (Thermo Scientific) or ECL Prime (Amersham) for 3 min, exposed to an X-ray film and visualized by autoradiography. Western blots for AKT (pan), Smad2/3 and bactin were carried out in parallel as loading controls. The relative intensities of specific protein bands were determined by QuantityOne image analysis software.
Scratch wound assay
The migratory properties of DU145, PC3, and LNCaP cells were measured using a scratch wound assay. Cells were plated in 6-well plates (5 9 10 5 cells/well) in MEM with 5 % FBS and cultured overnight. Before treatment, wells were scratched down the middle with a 200 ll pipette tip. Culture media were replaced with MEM containing 0.1 % FBS and cells were treated with TGFb1 or TGFb3 (1 ng/ml) with or without specific inhibitors of TGFbRI (SB431542: 5 lM), Smad3 (SIS3: 3 lM) or PI3-kinase (LY294002: 10 lM). Cells were allowed to migrate across the scratch for 48 h. Images of the scratch area were recorded at three random spots at 0 and 48 h. The migrating cells were counted using a standard size field for each image. Statistical analysis was performed using students t test (n = 3) with SigmaPlot Analysis Software.
Invasion assay
The invasive properties of DU145 and PC3 were measured using the BD BioCoat Matrigel Invasion inserts. Inserts (BD Biosciences) were coated with 50 ll of a 1:4 Matrigel/ Medium dilution (BD Biosciences) and allowed to solidify at 37°C for 1 h. Cells were resuspended (5 9 10 4 cells/ml) in MEM with 0.1 % FBS and 500 ll of cell suspension was added to each insert. Cells were treated with or without specific inhibitors of TGFbRI (SB431542: 5 lM), Smad3 (SIS3: 3 lM) or PI3-kinase (LY294002: 10 lM) followed by TGFb1 or TGFb3 (0.1, 1 or 10 ng/ml) and allowed to invade through a porous membrane coated with Matrigel at 37°C for 48 h. Matrigel and non-invading cells were removed via scrubbing. Invading cells on the membrane were fixed in 3.7 % paraformaldehyde and stained using the HEMA3 stain set (Fisher). Pictures were taken in five different fields for average number of invading cells to be determined. Statistical analyses were performed using students t test (n = 4) with SigmaPlot Analysis Software.
MTT assay PZ-HPV7, DU145 and PC3 cells were used as target cells for the detection of any differences in the bioactivity of recombinant TGFb isoforms using CellTiter 96 NonRadioactive Cell Proliferation Assay (Promega) [37, 38] . Cells were seeded (5 9 10 3 cells/well) in 96-well plates in recommended growth media. After allowing cells to attach overnight, medium was replaced and recombinant TGFb1 or TGFb3 were added at the concentration of 1 and 10 ng/ml and incubated for 48 h at 37°C. After 48 h, medium was again replaced and 15 ll Dye Solution added and incubated at 37°C in the dark for 4 h. Following 4 h incubation, solubilization/stop solution was added and incubated for 1 h. Absorbance was read at 570 nm using a 96-well plate reader. Three independent experiments were carried out with similar results.
Results
Gene and protein expression of TGFb isoforms, receptors and Smad proteins in prostate cell lines
Gene expression of TGFb isoforms and receptors in prostate cells was determined by RT-PCR across several established cell lines, with L-19 used as a control (Fig. 1a) . TGFb1 mRNA was expressed across all seven cell lines (PZ-HPV7, RWPE1, RWPE2, DU145, PC3, PC3M and LNCaP); however the expression was substantially lower in LNCaP cells. TGFb2 mRNA was detected in six of the seven cell lines with low expression in PZ-HPV7, RWPE1 and RWPE2 cells. A slight increase was detected in cancer cell lines DU145, PC3 and PC3M, however there was no detectable expression of TGFb2 in LNCaP cells.
TGFb3 expression was relatively low in normal prostate epithelial cell line PZ-HPV7 and in LNCaP cells, and was slightly higher in RWPE1 and RWPE2 cells, as well as in DU145 cells. The highest expression of TGFb3 was found in PC3 and PC3M cells, both metastatic prostate cancer cell lines.
TGFbRI mRNA was expressed throughout all seven cell lines, with LNCaP cells again having the lowest expression. TGFbRII was expressed in PZ-HPV7, RWPE1, RWPE2, DU145, PC3 and PC3M cells; however it was not detected in LNCaP cells. TGFbRIII was detected at low levels in PZ-HPV7, RWPE1, RWPE2, DU145, PC3, and PC3M cells, however it was not detected in LNCaP cells. The mRNA expression of Smad2 and Smad3 (R-Smads), Smad4 (Co-Smad) and Smad7 (I-Smad) were detected in all seven cell lines.
Western blot analysis was performed to determine relative protein abundance of TGFb isoforms (TGFb1, 2 and 3) in total cell lysates from PZ-HPV7, RWPE1, RWPE2, DU145, PC3 and PC3M cells (Fig. 1b) and for TGFbRII in cancer cell lines LNCaP, DU145 and PC3 cells (Fig. 1c) . All cells were cultured under standard growth conditions. TGFb1 (50kd precursor protein) was expressed across all cell lines, while TGFb2 (25kd mature protein) was detected only in PC3 and PC3 M cells. TGFb3 (50kd precursor protein) was detected in all cell lines, with high levels in metastatic cell lines DU145, PC3 and PC3M cells. TGFbRII protein was detected in DU145 and PC3 cells, however it was absent in LNCaP cells. LNCaP cells were included in future assays as a negative control to rule out non-specific effects of TGFb isoforms as LNCaP cells do not contain mRNA or protein signaling TGFbRII.
These studies showed an increase in both gene and protein expression of TGFb3 in metastatic cell lines DU145 and PC3 cells suggesting a possible autocrine role of this isoform in migration and invasion. Therefore, for further studies, DU145 and PC3 cell lines were selected to determine migratory and invasive potential in response to exogenous TGFb1 and TGFb3. Both DU145 and PC3 cells express all of the TGFb ligands, receptors and Smad proteins.
Differential effects of TGFb isoforms on proliferation, migration and invasion of prostate cancer cells
TGFb is known to inhibit proliferation in normal prostate epithelial cells [39] . The effects of TGFb1 and TGFb3 on the proliferation of immortalized normal epithelial (PZ-HPV7) cells and prostate cancer cell lines DU145 and PC3 were determined using MTT assay in order to rule out possible differences in the biopotencies of recombinant proteins. Figure 2a shows that both TGFb1 and TGFb3 significantly inhibited PZ-HPV7 and DU145 cell proliferation at both 1 and 10 ng/ml, with no differences in the potencies of the two isoforms. PC3 cells did not respond to the inhibitory effects of either isoform. The effects of TGFb1 and TGFb3 on migration of metastatic prostate cancer cell lines PC3, DU145 and LNCaP were determined using a scratch wound assay. PC3, DU145 and LNCaP cells were treated with either TGFb isoform and allowed to migrate according to established procedures. As shown in Fig. 2b , both TGFb isoforms caused an increase in the migration of PC3 cells. However, TGFb3 effects were 2.1 fold (n = 3) higher than those of TGFb1 on number of migrating cells (See Fig. 3b ; P \ 0.01). Both TGFb isoforms had no effects on the migration of DU145 and LNCaP cells under similar experimental conditions.
As shown in Fig. 2c , both TGFb1 and TGFb3 increased invasiveness of PC3 cells. TGFb1 had a significant effect on invasion at 0.1 ng/ml (P \ 0.05), which declined at both 1 and 10 ng/ml doses. However, TGFb3 caused significantly higher invasion of PC3 cells compared to TGFb1 at 1 ng/ml (P \ 0.05) and 10 ng/ml (P \ 0.01) doses (Fig. 2d ). Both TGFb isoforms had no effect on invasiveness of DU145 cells under identical experimental conditions.
The role of TGFbRI and Smad3 on TGFb isoform induced migration and invasion
To determine whether TGFb1 and TGFb3 effects on cell migration and invasion are mediated by classical TGFb signaling pathway, PC3 cells were treated with TGFb1 or TGFb3 in the presence of specific inhibitors of TGFbRI and Smad3. As shown in Fig. 3a, b , both TGFbRI inhibitor (SB431542) and Smad3 Inhibitor (SIS3) blocked TGFb1 and TGFb3 induced migratory effects on PC3 cells. TGFbRI inhibitor (SB431542) and Smad3 inhibitor (SIS3) also blocked the effects of TGFb isoforms on invasive behavior of PC3 cells (Fig. 3c, d ).
Differential effects of TGFb isoforms on migration and invasion are mediated by PI3K pathway
To determine if TGFb isoform-induced migration and invasion is mediated via the PI3-kinase pathway, scratch wound and invasion assays were performed in the presence or absence of a specific PI3-kinase inhibitor (LY294002: 10 lM). PC3 Cells were treated with TGFb1 or TGFb3 (1 ng/ml) and allowed to migrate across a scratch or through a matrigel-coated membrane for 48 h. PI3-kinase inhibitor (LY294002) blocked both TGFb1 and TGFb3 induced migratory behavior in PC3 cells (Fig. 3a, b) . PI3-kinase inhibitor (LY294002) also blocked the effects of both isoforms on the invasion of PC3 cells (Fig. 3c, d ).
Differential effects of TGFb isoforms on activation of PI3-kinase pathway
To determine if TGFb isoforms differentially activate the PI3-kinase pathway and phosphorylation of AKT (pAKT), PC3 cells were treated with either TGFb1 or TGFb3 (5 ng/ml) for specific time points and probed for pAKT ser473 , a downstream target of PI3-kinase. Both TGFb isoforms induced an increase in the phosphorylation of AKT ser473 over several time points in PC3 cells. TGFb3 was more effective than TGFb1 in increasing pAKT ser473 (data not shown). We then compared TGFb isoform induced pAKT ser473 in DU145, PC3 and LNCaP cells 15 and (Fig. 4a, b) . Once again, TGFb3 was more effective at inducing the phosphorylation of AKT ser473 with a significant (3.7 fold; n = 3) increase at 60 min as determined by densitometry using b-actin as a control. However, neither TGFb isoform increased pAKT ser473 levels in DU145 or LNCaP cells at both time points.
To determine whether TGFb1 and TGFb3 induced pAKT ser473 are mediated by TGFbRI, Smad3 or PI3-kinase pathway, PC3 cells were treated with a TGFbRI inhibitor (SB431542), Smad3 inhibitor (SIS3) or PI3-kinase inhibitor (LY294002) followed by TGFb1 or TGFb3 (5 ng/ml). Cell lysates were collected and analyzed for pAKT ser473 , Total AKT (pan) and b-actin. Both TGFbRI inhibitor (SB431542) and Smad3 inhibitor (SIS3) blocked TGFbinduced pAKT ser473 (Fig. 5a ). PI3-kinase inhibitor (LY294002) also blocked basal and TGFb-induced accumulation of pAKT ser473 in PC3 cells. We also looked at the phosphorylation of Smad 2 and Smad3 upon treatment with the same inhibitors (Fig. 5b) . SB431542 blocked the effects of both TGFb1 and TGFb3 on phosphorylation of Smad2 and Smad3. SIS3 blocked effects of both isoforms on Smad3 phosphorylation without affecting the phosphorylation of Smad2. LY294002 did not influence Smad2 or Smad3 phosphorylation in response to both isoforms.
Discussion
This study is the first of its kind to systematically determine the expression of all TGFb isoforms, receptors and Smads simultaneously in several prostate cell lines. Though previous studies have shown the presence of TGFb isoforms and machinery in different cancers including prostate tissues and cell lines, none have looked at the relative mRNA and protein expression levels in numerous prostate cell lines under the same experimental conditions. We have shown that TGFb1 is ubiquitously expressed at both the mRNA and protein level in both normal and metastatic prostate cell lines. This suggests that any differential effects seen in the normal versus metastatic cell lines may be due to changes in expression of other TGFb isoforms. Alternatively, post translation activation may play a role in changing effects of TGFb1 during different stages of prostate cancer. We show an increase of both TGFb2 and TGFb3 in metastatic prostate cell lines, however TGFb2 protein expression changes were only seen in PC3 cells. The steadiest change was seen in TGFb3 expression, with it increasing consistently in the more metastatic cell lines. This may indicate a specific role of TGFb3 in the metastatic phenotype. This differential isoform role is supported by similar high expression of TGFb3 in breast carcinomas correlating with decreased overall survival rate [40, 41] and that TGFb3 increased invasiveness of endometrial carcinoma cells [24] .
Based on our expression data, we compared the effects of TGFb1 and TGFb3 on the motility of three metastatic prostate cancer cell lines, DU145, PC3 and LNCaP cells. We show that both DU145 and PC3 cells express TGFb1 and TGFb3 as well as all receptors and Smad proteins, whereas LNCaP lacks the TGFbRII, a necessary receptor for TGFb signaling. In addition, both TGFb isoforms induce phosphorylation of Smad2/3 in both cell lines to the same extent (Unpublished data). However, while both TGFb isoforms induced migratory and invasive behavior in PC3 cells, DU145 and LNCaP cells were unresponsive to both isoforms under identical experimental conditions. Our ongoing studies on the effects of TGFb on cell proliferation show opposite results. While TGFb inhibits proliferation in DU145 cells, it has no effect on proliferation of PC3 cells (Strong et al., unpublished data). TGFb is known to exert differential effects depending on the context of the cell. These two cell lines may represent a model of the proposed TGFb ''switch'' from its tumor suppressor to tumor promoter activities.
We also show that both TGFb1 and TGFb3 increase migration and invasion of PC3 cells; however, TGFb3 is significantly more potent than TGFb1. These differences do not appear to be a consequence of differential bioactivities of the two recombinant proteins, since no differences were observed in the effects of the two isoforms on proliferation of normal prostate epithelial derived PZ-HPV7 cells and prostate cancer cell lines DU145 and PC3. The differential and more potent effects of TGFb3 on invasive behavior of prostate cancer cells are similar to those previously reported on TGFb3 induced invasiveness of endometrial carcinoma cells [24] . Prior studies have also revealed that TGFb isoform-specific effects can be both dependent or independent of Smad signaling depending on the context in which it is studied [24, 32, 33] . Our study indicates that the TGFb isoform-specific increase of migration and invasion is TGFbRI and Smad3 dependent.
The PI3-kinase pathway has been shown to play an essential role in the migration and invasion of many cell types. Previous studies indicate that TGFb can activate PI3-kinase, as shown by increased phosphorylation of AKT [29] [30] [31] [32] [33] , leading to increased invasion of cancer cells [24] . In keeping with these studies, our results indicate that the PI3-kinase pathway is essential for both TGFb1 and TGFb3 induced migration and invasion. Pharmacological inhibition of PI3-kinase blocks TGFb isoform-induced movement of PC3 cells. Both isoforms cause an increase in the phosphorylation of AKT in PC3 cells, with TGFb3 being more potent than TGFb1. This TGFb isoforminduced phosphorylation of AKT is both TGFbRI and Smad3 dependent. Our results also indicate that Smad2 may not mediate these effects of TGFb isoforms on AKT phosphorylation and invasive behavior.
These results, along with previous studies, confirm an isoform-specific role of TGFb in the migration and invasion of the metastatic PC3 prostate cancer cells which are dependent on the activation of the PI3-kinase pathway. We did not see similar effects of TGFb isoforms on activation of PI3-kinase and AKT phosphorylation in DU145 and LNCaP cells, indicating that lack of this response may be responsible for lack of TGFb effects on migration of these cells. It is tempting to speculate that the ability of TGFb to activate PI3-kinase signaling may be pre-requisite for the induction of invasive behavior in more advanced stages of prostate cancers and may represent the ''switch'' from antitumorigenic to tumor-promoter role of TGFb.
One possible contributor of differential effects of TGFb on activation of PI3-kinase DU145, LNCaP and PC3 cells may be the Phosphatase and Tensin Homolog (PTEN), which inhibits PI3-kinase dependent phosphorylation of AKT. PTEN has been shown to be mutated in many cancers which can lead to higher basal levels of pAKT ser473 and increased survival of cells [28, 42, 43] . PTEN is active in the DU145 cell line, but is mutated and biologically inactive in PC3 cells and absent from LNCaP cells altogether [44] [45] [46] [47] . Although LNCaP cells have higher basal levels of pAKT, we did not observe any effects of TGFb on pAKT ser473 , due to lack of TGFb signaling in these cells. It is therefore possible that PTEN plays a role in TGFb effects on activation of PI3-kinase in prostate cancer cells and that TGFb dependent invasive and metastatic behavior may be more pronounced in patients where the tumor cells harbor PTEN mutations. This suggests that PTEN and, ultimately, the PI3-kinase pathway may have a role in the TGFb isoform-induced migration and invasion and the TGFb ''switch'' from anti-to pro-tumorigenic cytokine in prostate cancer.
In conclusion, we show an increased expression of TGFb3 in cell line models of advanced prostate cancer and that this isoform is more potent than TGFb1 in activation of PI3-kinase signaling pathway and invasive behavior in these cells. We also show that the effects of TGFb isoforms on cell migration and invasion are mediated by both TGFbRI and Smad3 dependent activation of the PI3-kinase pathway and therefore simultaneous increase in TGFb3 expression and signaling and PTEN mutations may result in increased metastatic behavior of prostate cancer cells.
